Skip to content
10-K

Annual Report

Bolt Biotherapeutics, Inc. BOLT

0000950170-25-043873

← back to feed
Filed
Mar 24, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 19, 2025 38.34M sh
Shares Diluted FY 2024 · Dec 31, 2023 37.81M sh
Capex FY 2024 · Dec 31, 2023 $206K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$69.53M
Short Term Investments FY 2024 · Dec 31, 2023 $91.38M
Cash And Equivalents FY 2024 · Dec 31, 2023 $10.81M
Current Liabilities FY 2024 · Dec 31, 2023 $20.46M
Total Liabilities FY 2024 · Dec 31, 2023 $47.04M
Current Assets FY 2024 · Dec 31, 2023 $105.71M
Total Assets FY 2024 · Dec 31, 2023 $159.78M
Eps Diluted FY 2024 · Dec 31, 2023 −$1.83
Eps Basic FY 2024 · Dec 31, 2023 −$1.83
Sga Expense FY 2024 · Dec 31, 2023 $22.53M
Rd Expense FY 2024 · Dec 31, 2023 $61.54M
Net Income FY 2024 · Dec 31, 2023 −$69.2M
Operating Income FY 2024 · Dec 31, 2023 −$76.2M
Revenue FY 2024 · Dec 31, 2023 $7.88M
Stockholders Equity FY 2024 · Dec 31, 2022 $171.51M